Page 5 - சீஎபேர்த வில்லியம்ஸ் ஶ்யாஂக் இணை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Riskified Ltd Announces Launch of Initial Public Offering
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Munis underperform UST, remain cautious ahead of new-issues
bondbuyer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bondbuyer.com Daily Mail and Mail on Sunday newspapers.
Big competitive calendar to guide yields
bondbuyer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bondbuyer.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Acropolis Infrastructure Acquisition Corp. Announces Pricing of $300 Million Initial Public Offering
Acropolis Infrastructure Acquisition Corp.July 8, 2021 GMT
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) Acropolis Infrastructure Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 30,000,000 units at $10.00 per unit. The units will be listed on the New York Stock Exchange (the “NYSE”) under the symbol “ACRO.U” commencing on July 9, 2021. Each unit consists of one share of Class A common stock of the Company and one-third of one warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at an exercise price of $11.50 per share. Once the securities constituting the units begin separate trading, the Company expects the shares of Class A common stock and warrants will be listed on the NYSE under
Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock
July 01, 2021 21:50 ET | Source: Cerevel Therapeutics Cerevel Therapeutics Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 14,000,000 shares of common stock at a public offering price of $25.00 per share. The gross proceeds to Cerevel of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $350 million. The offering is expected to close on July 7, 2021, subject to customary closing conditions. In addition, Cerevel has granted the underwriters a 30-day option to purchase an additional 2,100,000 shares